Filtering by:
FDAFDA Approves Nerlynx (Neratinib) for a type of Breast Cancer
The US Food and Drug Administration (FDA) has approved the first extended adjuvant therapy for early-stage, HER2-postive breast cancer.
Panel Backs CAR T-cell Therapy for Leukemia: What You Need to Know and What’s Next
The US and Drug Administration (FDA) this week convened a panel of outside experts to weigh in on the readiness of a first-of-its-kind cancer treatment called CAR T-cell therapy. The panel unanimously recommended that the agency approve the treatment. What does this mean for patients? And is CAR T-cell therapy going to play an increasing role in cancer treatment in general? In this interview, Leonard Lichtenfeld, MD, MACP, American Cancer Society deputy chief medical officer, gives us his take.
FDA Approves New Targeted Therapy Drug Combination for Lung Cancer
The US Food and Drug Administration (FDA) has approved the targeted therapy drugs Tafinlar (dabrafenib) and Mekinist (trametinib) to be used together to treat people with a specific type of non-small cell lung cancer that has spread in the body (metastasized).
FDA Approves Keytruda (Pembrolizumab) for Any Tumor with Specific Genetic Change
The US Food and Drug Administration (FDA) has expanded the approval of the immunotherapy drug Keytruda (pembrolizumab) to include tumors with a specific genetic change regardless of cancer type.